Clinical trial
A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients…
NCT00492752 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00492752 |
|---|---|
| Title | A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma |
| Official title | A Randomized, Double-blinded, Placebo-controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Hepatocellular |
| Intervention type | Drug |
| Interventions | Sorafenib (Nexavar, BAY43-9006), Placebo |
| Enrollment | 226 |
| Start date | Oct 1, 2005 |
| Primary completion | Mar 1, 2007 |
| Completion | Jul 1, 2009 |
| First posted | Jun 27, 2007 |
| Last update posted | Apr 16, 2014 |
| Countries | China, South Korea, Taiwan |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: